Medasense

Medasense Biometrics develops AI-powered pain monitoring technology through its NOL (Nociception Level) Index, a continuous and non-invasive sensor platform that quantifies pain response to personalize treatment and avoid overmedication. The company's flagship product PMD-200 is used in critical care settings including operating rooms and ICUs to visualize pain response, commercially available in the United States, Europe, Canada, South Africa, UAE, Israel, and select Latin American countries. The pipeline product NOLedge applies Medasense's AI capabilities to pain prediction, stratification, and prevention strategies. Clinical studies demonstrate that NOL monitoring delivers a 33% reduction in reported postoperative pain, with proven impact on patient safety, outcomes, and cost savings. The company partners with Philips Capsule for EHR integration and collaborates with Jefferson Health on spine surgery studies. Founded in 2008 and headquartered in Ramat Gan, Israel, the company has raised approximately $26.6M in Series C funding. Medasense differentiates itself as the first company to quantify pain objectively, transforming pain assessment from subjective clinical judgment to data-driven personalized analgesia management.

Wearable Technology > Health and Wellness Devices > Chronic Pain,

Disease Self Management > Pain > Therapy > Chronic Pain > Device > Wearable,

Healthcare IT > Value Based Care > Remote Monitoring > Hardware > Other Devices,

Pain Management > Medical Devices > Monitoring Devices